Association of Pertuzumab, Trastuzumab, and Docetaxel Combination Therapy With Overall Survival in Patients With Metastatic Breast Cancer

This cohort study compares the findings of combined pertuzumab, trastuzumab, and docetaxel therapy in women with metastatic breast cancer with those in the CLEOPATRA trial.

Detalles Bibliográficos
Autores principales: Ramagopalan, Sreeram V., Pisoni, Riccardo, Rathore, Lokendra Singh, Ray, Joshua, Sammon, Cormac
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807287/
https://www.ncbi.nlm.nih.gov/pubmed/33439261
http://dx.doi.org/10.1001/jamanetworkopen.2020.27764
Descripción
Sumario:This cohort study compares the findings of combined pertuzumab, trastuzumab, and docetaxel therapy in women with metastatic breast cancer with those in the CLEOPATRA trial.

Ejemplares similares